What does 'selective' actually mean in the context of ACP-105 compared to anabolic steroids?

Selectivity means ACP-105 recruits different coactivator proteins depending on the tissue, producing strong anabolic signaling in muscle and bone but weak androgenic stimulation in the prostate and scalp. Classic steroids like testosterone activate the androgen receptor uniformly across all tissues, which drives both the anabolic benefit and androgenic side effects simultaneously. ACP-105 is designed to widen the gap between those two outcomes.

Are SARMs like ACP-105 genuinely safer than traditional steroids, or is that marketing?

Safer is context-dependent. ACP-105 produces less androgenic burden — reduced prostate stimulation, lower risk of DHT-driven hair loss, and minimal estrogenic conversion compared to aromatizing AAS. However, it still suppresses the hypothalamic-pituitary-gonadal axis, and long-term human safety data remain limited. The honest answer is 'a different and generally narrower side effect profile,' not 'safe.'

At what point does tissue selectivity break down with ACP-105?

Selectivity erodes at higher doses and longer cycle durations. As receptor occupancy increases across all tissues, the coactivator-recruitment advantage diminishes and androgenic signaling in non-target tissues rises. Preclinical data suggest that doses substantially above the studied range begin to mirror the suppression and androgenic activity profile of weaker steroidal compounds. Staying within the 5–10 mg research window preserves the selectivity benefit.

Can ACP-105 5mg tablets be split for a lower starting dose?

Yes. Each Vital Research ACP-105 tablet is scored and can be split to deliver approximately 2.5 mg per half, suitable for an introductory phase where users assess individual androgen sensitivity before escalating. Splitting should be done with a clean pill cutter to maintain dose uniformity and minimize powder loss.

How should ACP-105 tablets be stored to maintain potency?

Store tablets in a cool, dry location away from direct light and humidity — ideally between 15 °C and 25 °C. Keep the blister pack sealed until each tablet is needed, as repeated exposure to air and moisture can degrade the active compound over time. Do not store in a bathroom cabinet or near a heat source. (2) angle_used

Lab Tested

Vital Research

ACP-105 5mg/tab 30 Tablets by Vital Research

Name: ACP-105
Brand: Vital Research
SKU: SARM-ACP-VIT-001
Price: 48.00 EUR
Availability: InStock

ACP-105 is a non-steroidal selective androgen receptor modulator (SARM) formulated at 5 mg per tablet, distinguished from classic anabolic-androgenic steroids by its tissue-selective receptor binding — activating anabolic pathways in muscle and bone while exerting far weaker androgenic influence on the prostate and skin. Each 30-tablet blister pack from Vital Research delivers a precise, orally administered dose without the need for injections or oil-based carriers. Quality is verified at every batch level: independent HPLC quantification confirms concentration accuracy, and LAL endotoxin testing clears each lot for safe consumption under GMP-compliant production standards.

€48.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Tissue-selective androgen receptor activation — strong muscle signaling, reduced prostate stimulation
5 mg per tablet allows precise, scalable dosing from 2.5 mg introductory to 10 mg advanced protocols
HPLC-verified concentration within ±5 % of label claim per production batch
LAL endotoxin testing confirms microbiological safety for each lot
Non-aromatizing compound — no conversion to estrogen under standard dosing conditions
Oral tablet format removes injection-related complications entirely
GMP-compliant manufacturing ensures consistent tablet uniformity across packs

Phase	Dosage	Note
Introductory (Weeks 1–2)	2.5 mg/day (½ tablet)	Assess individual androgen sensitivity; establishes selectivity baseline before escalation
Main Research Phase (Weeks 3–6)	5–10 mg/day (1–2 tablets, split AM/PM)	Split dosing maintains stable plasma levels given the ~3–4 h half-life; maximizes the anabolic-to-androgenic selectivity window
Taper / Transition (Weeks 7–8)	2.5–5 mg/day	Gradual reduction supports HPG axis recovery before PCT initiation; run bloodwork to confirm LH/FSH status

Key takeaways

Understand that ACP-105 targets androgen receptors with tissue-selective coactivator recruitment.
Expect less androgenic burden compared to classical anabolic-androgenic steroids.
Monitor LH and FSH levels — suppression still occurs despite selectivity advantages.
Split tablets to 2.5 mg for a conservative introductory dose escalation.
Confirm each batch via HPLC certification before beginning any protocol.

ACP-105 and the Science of Selectivity: How It Differs from Anabolic Steroids

ACP-105 is a partial agonist of the androgen receptor engineered to separate anabolic tissue activation from classical androgenic side effects — the defining distinction between modern SARMs and traditional anabolic-androgenic steroids (AAS). Classic AAS such as testosterone bind the androgen receptor indiscriminately across all tissues: skeletal muscle, prostate, sebaceous glands, scalp follicles, and the hypothalamic-pituitary axis all respond simultaneously, producing the well-documented androgenic burden. ACP-105 instead recruits coactivator proteins in a tissue-dependent pattern, yielding strong anabolic signaling in muscle and bone with measurably attenuated androgenic output in sensitive tissues.

Receptor Binding Mechanics and Comparative Potency

In preclinical assays, ACP-105 demonstrates an anabolic-to-androgenic ratio substantially more favorable than testosterone propionate at equivalent receptor-occupancy doses — a benchmark frequently cited in SARM pharmacology literature. The compound carries a reported half-life of approximately 3–4 hours in rodent models, supporting a twice-daily oral dosing strategy for humans seeking stable plasma levels. Vital Research tablets are HPLC-verified to ±5 % of the stated 5 mg dose, ensuring that the selectivity advantage documented in research is not undermined by concentration variance.

Where Selectivity Has Limits

SARMs are not side-effect-free; selectivity is a spectrum, not a binary state. ACP-105 still suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) via hypothalamic androgen receptor activation — meaning endogenous testosterone production is reduced in a dose- and duration-dependent manner. This suppression is generally milder compared to equivalent-anabolic doses of testosterone enanthate, but it is real and measurable via serum bloodwork. Users who overlook post-cycle hormonal recovery risk prolonged low-testosterone windows that negate lean-mass retention gains.

Practical Advantage of the Tablet Format

Oral tablet delivery eliminates injection-site complications and simplifies dose splitting for conservative escalation protocols. Each tablet scores cleanly, allowing a 2.5 mg introductory dose for users mapping individual androgen sensitivity before advancing to the standard 5–10 mg research range.

Usage

Obtain pre-cycle bloodwork including total testosterone, LH, FSH, and PSA to establish your hormonal baseline before selectivity comparison is meaningful.
Begin at 2.5 mg (½ tablet) daily for the first two weeks — this introductory step lets you map individual androgen receptor sensitivity within the selectivity framework of ACP-105.
Advance to 5 mg daily (one full tablet) if tolerability is confirmed; split into morning and evening administrations to account for the approximately 3–4 hour half-life and maintain steadier plasma levels.
Do not exceed 10 mg/day — higher doses progressively erode the tissue-selectivity advantage that differentiates ACP-105 from classical androgenic compounds.
Take each tablet with a small amount of food to support consistent absorption and minimize any gastrointestinal sensitivity.
At cycle end, run post-cycle bloodwork before deciding on PCT; even with the attenuated suppression profile of ACP-105, LH and FSH recovery must be confirmed before concluding the protocol.

Warnings

Contraindications: Not intended for individuals under 18 years of age, pregnant or breastfeeding individuals, or those with androgen-sensitive conditions including prostate hyperplasia or hormone-receptor-positive cancers. Individuals on anticoagulant therapy should consult a physician prior to use, as androgen receptor modulation can influence clotting factor expression.

Side Effects: Potential effects include dose-dependent suppression of endogenous testosterone via HPG axis interference, mild fatigue during hormonal transition, and, at elevated doses, early signs of androgenic activity (acne, increased perspiration). ACP-105 does not aromatize, so estrogen-driven effects such as gynecomastia are not a primary concern at studied doses.

Monitoring: Run serum testosterone, LH, FSH, and a full lipid panel at baseline, mid-cycle (week 4), and post-cycle. Liver enzyme panels (AST/ALT) are advisable for cycles exceeding six weeks. Track any prostate-related symptoms and discontinue if PSA values rise unexpectedly.

PCT: A structured post-cycle therapy protocol is recommended after cycles lasting four weeks or longer. Selective estrogen receptor modulators (SERMs) such as tamoxifen or clomiphene are commonly used to restart LH and FSH secretion. Begin PCT within 24–48 hours of the final ACP-105 dose and continue for 4 weeks, confirming hormonal recovery with bloodwork before discontinuing.

Frequently asked questions

What does 'selective' actually mean in the context of ACP-105 compared to anabolic steroids?: Selectivity means ACP-105 recruits different coactivator proteins depending on the tissue, producing strong anabolic signaling in muscle and bone but weak androgenic stimulation in the prostate and scalp. Classic steroids like testosterone activate the androgen receptor uniformly across all tissues, which drives both the anabolic benefit and androgenic side effects simultaneously. ACP-105 is designed to widen the gap between those two outcomes.
Are SARMs like ACP-105 genuinely safer than traditional steroids, or is that marketing?: Safer is context-dependent. ACP-105 produces less androgenic burden — reduced prostate stimulation, lower risk of DHT-driven hair loss, and minimal estrogenic conversion compared to aromatizing AAS. However, it still suppresses the hypothalamic-pituitary-gonadal axis, and long-term human safety data remain limited. The honest answer is 'a different and generally narrower side effect profile,' not 'safe.'
At what point does tissue selectivity break down with ACP-105?: Selectivity erodes at higher doses and longer cycle durations. As receptor occupancy increases across all tissues, the coactivator-recruitment advantage diminishes and androgenic signaling in non-target tissues rises. Preclinical data suggest that doses substantially above the studied range begin to mirror the suppression and androgenic activity profile of weaker steroidal compounds. Staying within the 5–10 mg research window preserves the selectivity benefit.
Can ACP-105 5mg tablets be split for a lower starting dose?: Yes. Each Vital Research ACP-105 tablet is scored and can be split to deliver approximately 2.5 mg per half, suitable for an introductory phase where users assess individual androgen sensitivity before escalating. Splitting should be done with a clean pill cutter to maintain dose uniformity and minimize powder loss.
How should ACP-105 tablets be stored to maintain potency?: Store tablets in a cool, dry location away from direct light and humidity — ideally between 15 °C and 25 °C. Keep the blister pack sealed until each tablet is needed, as repeated exposure to air and moisture can degrade the active compound over time. Do not store in a bathroom cabinet or near a heat source. (2) angle_used

Manufacturer

Vital Research was established with a single mandate: close the gap between academic SARM pharmacology and the reliability of finished consumer products. The company's origin story is rooted in frustration with the inconsistency that characterized the early research-chemical market — underdosed tablets, contaminated batches, and zero third-party accountability. To address this, Vital Research built its production infrastructure around GMP-aligned procedures from day one, incorporating independent HPLC quantification and LAL endotoxin screening as non-negotiable release criteria rather than optional add-ons. The brand publishes batch-specific certificates of analysis, positioning transparency as its core competitive differentiator in the selective androgen research space.

Product details

Brand	Vital Research
Active ingredient	acp-105
Also known as	acp-105, ACP-105, Vital Research acp-105
Strength	5 mg
Form	Tabletten
Pack size	30 pieces
Item number	SARM-ACP-VIT-001

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00

Stack it with

Pairs well with these products.

High Concentration